Pancreatic cancer targets and uses thereof

• US 7,473,531 B1
• Filed: 08/06/2004
• Issued: 01/06/2009
• Est. Priority Date: 08/08/2003
• Status: Expired due to Fees

• Current Assignee: Applied Biosystems LLC (Thermo Fisher Scientific Incorporated)
• Original Assignee: Applera Corporation (Thermo Fisher Scientific Incorporated)
• Inventors: Patterson, Scott, Narayan, Vaibhav, McCaffery, Ian, Domon, Bruno
• Primary Examiner(s): Helms; Larry R.
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US10/912,745
• Time in Patent Office: 1,614 Days
• Field of Search: 435/7.1, 435/7.23, 530/350, 530/387.1
• US Class Current: 435/7.1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4705 stimulating, promoting or activating activity
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 14/70596 Molecules with a "CD"-designation not provided for elsewhere
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C07K 14/745 Blood coagulation or fibrinolysis factors
• CPC Class Codes: C07K 14/8114 Kunitz type inhibitors
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/36 against blood coagulation factors
• CPC Class Codes: C07K 16/38 against protease inhibitors of peptide structure
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 16/4266 against anti-tumor receptor Ig
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1137 : against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 15/1138 : against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/14 : interfering N.A.
• CPC Class Codes: C12N 9/001 : acting on the CH-CH group of donors (1.3)
• CPC Class Codes: C12N 9/1044 : Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
• CPC Class Codes: C12N 9/14 : Hydrolases (3)
• CPC Class Codes: C12Q 1/6886 : for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 : Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/112 : Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 : Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 : Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 : Expression markers
• CPC Class Codes: C12Y 103/01071 : DELTA24 (24(1))-sterol reductase (1.3.1.71)
• CPC Class Codes: C12Y 203/02013 : Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
• CPC Class Codes: C12Y 306/03009 : Na+/K+-exchanging ATPase (3.6.3.9)
• CPC Class Codes: G01N 2500/00 : Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/57438 : of liver, pancreas or kidney
• CPC Class Codes: Y10T 436/25 : including sample preparation

Abstract

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Claims

1. A method of diagnosing pancreatic cancer in an individual, the method comprising detecting a higher level of ASCT2 protein in a sample from the individual as compared to levels of ASCT2 protein in pancreatic tissues of healthy individuals, wherein the amino acid sequence of the ASCT2 protein comprises SEQ ID NO:

56, and wherein the higher level of ASCT2 protein indicates that said individual has pancreatic cancer.

2. The method of claim 1, wherein the ASCT2 protein is detected by contacting the sample with an isolated antibody that selectively binds to the ASCT2 protein and determining the extent or binding of the antibody to the ASCT2 protein.

3. The method of claim 2, wherein the antibody is coupled to a detectable substance.